Literature DB >> 1515723

Transcatheter atrial septal defect occlusion devices: normal radiographic appearances and complications.

A E Schlesinger1, S J Folz, R H Beekman.   

Abstract

Three transcatheter atrial septal defect (ASD) occlusion devices have been used in clinical trials during the past decade: the Rashkind ASD occluder, the Lock Clamshell occluder, and the buttoned double-disk device. The normal radiographic appearance of these three devices and radiographic findings in complications are presented. Of 12 transcatheter ASD occlusions performed, the buttoned double-disk device was used in eight patients, the Rashkind ASD occluder in three, and the Lock Clamshell occluder in one. Complications included both improper placement and partial dislodgment of the Rashkind ASD occluder device (n = 2), fracture of a metal arm of the Lock Clamshell device (n = 1), and detachment of the buttoned double-disk device with embolization into the right pulmonary artery (n = 1). Knowledge of the normal radiographic appearance of ASD occlusion devices and the findings in various complications will be necessary for radiologists as transcatheter ASD closure becomes more commonplace. Chest radiography is the primary method of detecting short- and long-term complications in patients following transcatheter ASD closure.

Entities:  

Mesh:

Year:  1992        PMID: 1515723     DOI: 10.1016/s1051-0443(92)72007-7

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  2 in total

1.  Transcatheter closure of atrial septal defect and interatrial communications with a new self expanding nitinol double disc device (Amplatzer septal occluder): multicentre UK experience.

Authors:  K C Chan; M J Godman; K Walsh; N Wilson; A Redington; J L Gibbs
Journal:  Heart       Date:  1999-09       Impact factor: 5.994

Review 2.  Radiology of cardiac devices and their complications.

Authors:  J Dipoce; A Bernheim; H Spindola-Franco
Journal:  Br J Radiol       Date:  2014-11-20       Impact factor: 3.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.